サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1541332

エリスロポエチン製剤市場レポート：薬剤クラス別、製品タイプ別、用途別、エンドユーザー別、地域別、2024～2032年

Erythropoietin Drugs Market Report by Drug Class, Product Type, Application, End-User, and Region 2024-2032

出版日
発行
IMARC
ページ情報
英文 140 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.57円
エリスロポエチン製剤市場レポート：薬剤クラス別、製品タイプ別、用途別、エンドユーザー別、地域別、2024～2032年
出版日: 2024年08月10日
発行: IMARC
ページ情報: 英文 140 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のエリスロポエチン製剤市場規模は2023年に110億米ドルに達しました。今後、IMARC Groupは、市場は2032年までに173億米ドルに達し、2024～2032年の間に5％の成長率（CAGR）を示すと予測しています。貧血とがんの有病率の増加、慢性腎臓病の治療への応用の増加、薬剤の潜在的効果に関する大衆の意識の高まりが、市場を牽引する主要要因のいくつかです。

エリスロポエチン（EPO）製剤は、エポエチンアルファ、エポエチンベータ、ダルベポエチンアルファなど様々な薬剤で構成され、体内のEPO欠乏症を治療するために消費されます。これらは組換えデオキシリボ核酸（DNA）技術を用いて合成的に製造されます。骨髄における赤血球（RBC）の産生を刺激し、体内のヘモグロビン濃度を調整します。体内の赤血球の量を健康な状態に保ちながら、持久力の強化、疲労感の軽減、代謝の向上、筋肉の治癒プロセスの改善を助ける。貧血、末期腎不全、ヒト免疫不全ウイルス（HIV）、血液学など、さまざまな疾患の治療に利用されています。このほか、EPO製剤は、筋肉への酸素供給能力を高める効果があるため、アスリートのパフォーマンスや有酸素運動能力を向上させるために消費されています。

エリスロポエチン製剤市場傾向

現在、がんや神経疾患（自閉症、脳腫瘍、脳性麻痺、てんかん、注意欠陥障害（ADD）など）の有病率の増加により、大衆の間でEPO製剤に対する需要が高まっていることは、市場の成長を支える重要な要因の一つです。これに加えて、EPO薬とその有効性に関する大衆の意識の高まりが、市場の展望を明るいものにしています。さらに、世界中の大衆の間で外科的介入の必要性が高まっています。これは、患者の外科手術後の同種輸血を減らすためにEPO薬の利用が増加していることと相まって、市場の成長を促進しています。これとは別に、世界中の個人における慢性腎臓病（CKD）患者数の増加が、業界の投資家に有利な成長機会を提供しています。さらに、赤血球（RBC）の増加や疲労の軽減など、EPO薬が提供するさまざまな利点が市場にプラスの影響を与えています。これに加えて、世界中でエリスロポエチンバイオシミラーが急速に商業化されていることも、市場の成長を後押ししています。このことは、世界中で参照薬よりもバイオシミラー医薬品を好む傾向が強まっていることと相まって、市場の成長に寄与しています。さらに、新規治療としてEPO製剤が研究機関で多くの研究目的で利用されるようになっていることも、市場の成長を強めています。

本レポートで扱う主要質問

  • エリスロポエチン製剤市場の世界市場規模は？
  • 2024～2032年における世界のエリスロポエチン製剤市場の予想成長率は？
  • 世界のエリスロポエチン製剤市場を牽引する主要因は何か？
  • 世界のエリスロポエチン製剤市場に対するCOVID-19の影響は？
  • エリスロポエチン製剤市場の薬剤クラス別内訳は？
  • 世界のエリスロポエチン製剤市場の製品タイプ別内訳は？
  • 世界のエリスロポエチン製剤市場の用途別内訳は？
  • 世界のエリスロポエチン製剤市場のエンドユーザー別内訳は？
  • エリスロポエチン製剤市場の世界における主要地域は？
  • 世界のエリスロポエチン製剤市場における主要参入企業は？

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査の目的
  • ステークホルダー
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要業界動向

第5章 世界のエリスロポエチン製剤市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳：薬剤クラス別

  • 生物製剤
  • バイオシミラー

第7章 市場内訳：製品タイプ別

  • エポエチンアルファ
  • エポエチンベータ
  • ダルベポエチンアルファ
  • その他

第8章 市場内訳：用途別

  • 血液学
  • 腎臓疾患
  • がん
  • その他

第9章 市場内訳：エンドユーザー別

  • 病院
  • 在宅医療
  • 専門クリニック
  • その他

第10章 市場内訳：地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳：国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Amgen Inc.
    • Biocon Limited
    • Dr. Reddy's Laboratories Ltd.
    • F. Hoffmann-La Roche AG
    • Intas Pharmaceuticals Ltd.
    • Johnson & Johnson
    • LG Chem Ltd.
    • Pfizer Inc.
    • Sun Pharmaceutical Industries Limited
    • Teva Pharmaceutical Industries Ltd.
図表

List of Figures

  • Figure 1: Global: Erythropoietin Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Erythropoietin Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Erythropoietin Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Erythropoietin Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 5: Global: Erythropoietin Drugs Market: Breakup by Product Type (in %), 2023
  • Figure 6: Global: Erythropoietin Drugs Market: Breakup by Application (in %), 2023
  • Figure 7: Global: Erythropoietin Drugs Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Erythropoietin Drugs Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Erythropoietin Drugs (Biologics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Erythropoietin Drugs (Biologics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Erythropoietin Drugs (Biosimilars) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Erythropoietin Drugs (Biosimilars) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Erythropoietin Drugs (Epoetin-alfa) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Erythropoietin Drugs (Epoetin-alfa) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Erythropoietin Drugs (Epoetin-beta) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Erythropoietin Drugs (Epoetin-beta) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Erythropoietin Drugs (Darbepoetin-alfa) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Erythropoietin Drugs (Darbepoetin-alfa) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Erythropoietin Drugs (Other Product Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Erythropoietin Drugs (Other Product Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Erythropoietin Drugs (Hematology) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Erythropoietin Drugs (Hematology) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Erythropoietin Drugs (Kidney Disorder) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Erythropoietin Drugs (Kidney Disorder) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Erythropoietin Drugs (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Erythropoietin Drugs (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Erythropoietin Drugs (Other Applications) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Erythropoietin Drugs (Other Applications) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Erythropoietin Drugs (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Erythropoietin Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Erythropoietin Drugs (Homecare) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Erythropoietin Drugs (Homecare) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Erythropoietin Drugs (Specialty Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Erythropoietin Drugs (Specialty Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Erythropoietin Drugs (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Erythropoietin Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: North America: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: North America: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: United States: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: United States: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Canada: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Canada: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Asia-Pacific: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Asia-Pacific: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: China: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: China: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Japan: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Japan: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: India: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: India: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: South Korea: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: South Korea: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Australia: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Australia: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Indonesia: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Indonesia: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Others: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Others: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Europe: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Europe: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Germany: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Germany: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: France: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: France: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: United Kingdom: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: United Kingdom: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Italy: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Italy: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Spain: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Spain: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Russia: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Russia: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Others: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Others: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Latin America: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Latin America: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Brazil: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Brazil: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Mexico: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Mexico: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Others: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Others: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Middle East and Africa: Erythropoietin Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Middle East and Africa: Erythropoietin Drugs Market: Breakup by Country (in %), 2023
  • Figure 85: Middle East and Africa: Erythropoietin Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Global: Erythropoietin Drugs Industry: SWOT Analysis
  • Figure 87: Global: Erythropoietin Drugs Industry: Value Chain Analysis
  • Figure 88: Global: Erythropoietin Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Erythropoietin Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Erythropoietin Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Erythropoietin Drugs Market Forecast: Breakup by Product Type (in Million US$), 2024-2032
  • Table 4: Global: Erythropoietin Drugs Market Forecast: Breakup by Application (in Million US$), 2024-2032
  • Table 5: Global: Erythropoietin Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Erythropoietin Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Erythropoietin Drugs Market: Competitive Structure
  • Table 8: Global: Erythropoietin Drugs Market: Key Players
目次
Product Code: SR112024A4270

The global erythropoietin drugs market size reached US$ 11.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 17.3 Billion by 2032, exhibiting a growth rate (CAGR) of 5% during 2024-2032. The growing prevalence of anemia and cancer, increasing application in treating chronic kidney disease, and rising awareness among the masses about the potential effects of the drug represent some of the key factors driving the market.

Erythropoietin (EPO) drugs comprise various drugs, such as epoetin-alfa, epoetin-beta, and darbepoetin-alfa, that are consumed to cure EPO deficiency in the body. They are manufactured synthetically using recombinant deoxyribonucleic acid (DNA) technology. They stimulate the production of red blood cells (RBCs) in bone marrow and regulate the concentration of hemoglobin in the body. They assist in enhancing endurance, reducing tiredness, increasing metabolism, and improving the healing process of muscles while maintaining a healthy amount of erythrocytes in the body. They are utilized to treat various diseases, such as anemia, end-stage renal disease, human immunodeficiency virus (HIV), and hematology, among individuals. Besides this, EPO drugs are consumed by athletes to enhance their performance and aerobic capacity, as they benefit in increasing the availability of oxygen to their muscles.

Erythropoietin Drugs Market Trends:

At present, the rising demand for EPO drugs among the masses due to the increasing prevalence of cancer and neurological diseases, such as autism, brain tumors, cerebral palsy, epilepsy, and attention deficit disorder (ADD), among individuals represents one of the key factors supporting the growth of the market. Besides this, the growing awareness among the masses about the EPO drugs and their effectiveness is offering a positive market outlook. Additionally, there is a rise in the need for surgical interventions among the masses around the world. This, coupled with the increasing utilization of EPO drugs to reduce allogeneic blood transfusions after surgical procedures in patients, is propelling the growth of the market. Apart from this, the rising number of chronic kidney disease (CKD) cases among individuals across the globe are offering lucrative growth opportunities to industry investors. Moreover, various benefits offered by EPO drugs, such as increasing red blood cells (RBCs) and reducing fatigue, are positively influencing the market. In addition to this, the rapid commercialization of erythropoietin biosimilars around the world is impelling the growth of the market. This, coupled with the increasing preference for biosimilar drugs rather than reference drugs across the globe, is contributing to the growth of the market. Furthermore, the rising utilization of EPO drugs as novel therapeutic agents in research institutes for numerous research purposes is strengthening the growth of the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global erythropoietin drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, product type, application and end user.

Drug Class Insights:

Biologics

Biosimilars

The report has provided a detailed breakup and analysis of the erythropoietin drugs market based on the drug class. This includes biologics and biosimilars. According to the report, biologics represented the largest segment.

Product Type Insights:

Epoetin-alfa

Epoetin-beta

Darbepoetin-alfa

Others

A detailed breakup and analysis of the erythropoietin drugs market based on the product type has also been provided in the report. This includes epoetin-alfa, epoetin-beta, darbepoetin-alfa, and others. According to the report, epoetin-alfa accounted for the largest market share.

Application Insights:

Hematology

Kidney Disorder

Cancer

Others

A detailed breakup and analysis of the erythropoietin drugs market based on the application has also been provided in the report. This includes hematology, kidney disorder, cancer, and others. According to the report, kidney disorder accounted for the largest market share.

End-User Insights:

Hospitals

Homecare

Specialty Clinics

Others

A detailed breakup and analysis of the erythropoietin drugs market based on the end-user has also been provided in the report. This includes hospitals, homecare, specialty clinics, and others. According to the report, hospitals accounted for the largest market share.

Regional Insights:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America (the United States and Canada) was the largest market for erythropoietin drugs. Some of the factors driving the North America erythropoietin drugs market included the increasing approvals of erythropoietin drugs, various incentives offered by governing agencies for research on chronic diseases, rising prevalence of cancer among individuals, etc.

Competitive Landscape:

The report has also provided a comprehensive analysis of the competitive landscape in the global erythropoietin drugs market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Amgen Inc., Biocon Limited, Dr. Reddy's Laboratories Ltd., F. Hoffmann-La Roche AG, Intas Pharmaceuticals Ltd., Johnson & Johnson, LG Chem Ltd., Pfizer Inc., Sun Pharmaceutical Industries Limited, Teva Pharmaceutical Industries Ltd., etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

Key Questions Answered in This Report

  • 1. How big is the global erythropoietin drugs market?
  • 2. What is the expected growth rate of the global erythropoietin drugs market during 2024-2032?
  • 3. What are the key factors driving the global erythropoietin drugs market?
  • 4. What has been the impact of COVID-19 on the global erythropoietin drugs market?
  • 5. What is the breakup of the global erythropoietin drugs market based on the drug class?
  • 6. What is the breakup of the global erythropoietin drugs market based on the product type?
  • 7. What is the breakup of the global erythropoietin drugs market based on the application?
  • 8. What is the breakup of the global erythropoietin drugs market based on the end-user?
  • 9. What are the key regions in the global erythropoietin drugs market?
  • 10. Who are the key players/companies in the global erythropoietin drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Erythropoietin Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Biologics
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Biosimilars
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast

7 Market Breakup by Product Type

  • 7.1 Epoetin-alfa
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Epoetin-beta
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Darbepoetin-alfa
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Others
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Application

  • 8.1 Hematology
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Kidney Disorder
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Cancer
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4 Others
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Hospitals
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Homecare
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3 Specialty Clinics
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast
  • 9.4 Others
    • 9.4.1 Market Trends
    • 9.4.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Amgen Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2 Biocon Limited
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3 Dr. Reddy's Laboratories Ltd.
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4 F. Hoffmann-La Roche AG
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
    • 15.3.5 Intas Pharmaceuticals Ltd.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Johnson & Johnson
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
      • 15.3.6.4 SWOT Analysis
    • 15.3.7 LG Chem Ltd.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
      • 15.3.7.4 SWOT Analysis
    • 15.3.8 Pfizer Inc.
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9 Sun Pharmaceutical Industries Limited
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10 Teva Pharmaceutical Industries Ltd.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis